Patents by Inventor Werner Lesslauer
Werner Lesslauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8163522Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.Type: GrantFiled: May 19, 1995Date of Patent: April 24, 2012Assignee: Hoffman-LaRoche Inc.Inventors: Manfred Brockhaus, Reiner Gentz, Dembic Zlatko, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
-
Patent number: 8063182Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.Type: GrantFiled: May 19, 1995Date of Patent: November 22, 2011Assignee: Hoffman-LaRoche Inc.Inventors: Manfred Brockhaus, Reiner Gentz, Dembic Zlatko, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
-
Publication number: 20030175895Abstract: The present invention relates to the discovery of novel genes and proteins, which function in pathways involved in brain pathogenesis. In particular, the novel genes and proteins relate to inflammatory tissue responses caused by brain injuries such trauma, ischemia or autoimmune-inflammation or other diseases or processes related to neuroinflammation. The compounds disclosed in the present invention are useful as therapeutics, diagnostics and in screening assays.Type: ApplicationFiled: January 16, 2003Publication date: September 18, 2003Inventors: Werner Lesslauer, Ulrike Utans-Schneitz
-
Patent number: 6537794Abstract: The present invention relates to the discovery of novel genes and proteins, which function in pathways involved in brain pathogenesis. In particular, the novel genes and proteins relate to inflammatory tissue responses caused by brain injuries such trauma, ischemia or autoimmune-inflammation or other diseases or processes related to neuroinflammation. The compounds disclosed in the present invention are useful as therapeutics, diagnostics and in screening assays.Type: GrantFiled: October 25, 1999Date of Patent: March 25, 2003Assignee: Hoffmann-La Roche Inc.Inventors: Werner Lesslauer, Ulrike Utans-Schneitz
-
Patent number: 6057426Abstract: The present invention relates to the discovery of novel genes and proteins, which function in pathways involved in brain pathogenesis. In particular, the novel genes and proteins relate to inflammatory tissue responses caused by brain injuries such trauma, ischemia or autoimmune-inflammation or other diseases or processes related to neuroinflammation. The compounds disclosed in the present invention are useful as therapeutics, diagnostics and in screening assays.Type: GrantFiled: April 30, 1998Date of Patent: May 2, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Werner Lesslauer, Ulrike Utans-Schneitz
-
Patent number: 5808029Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.Type: GrantFiled: May 19, 1995Date of Patent: September 15, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Manfred Brockhaus, Zlatko Dembic, Reiner Gentz, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
-
Patent number: 5610279Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.Type: GrantFiled: July 21, 1993Date of Patent: March 11, 1997Assignee: Hoffman-La Roche Inc.Inventors: Manfred Brockhaus, Zlatko Dembic, Reiner Gentz, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
-
Patent number: 5597899Abstract: Human TNF muteins having higher binding affinity for human p75-TNF receptor than for human p55-TNF receptor include muteins having at least one different amino acid relative to wild-type human TNF at a position corresponding to position 33, 65, 67, 75, 87, 143, 145 or 147 of the wild-type amino acid sequence.Type: GrantFiled: March 24, 1994Date of Patent: January 28, 1997Assignee: Hoffmann-La Roche Inc.Inventors: David Banner, Werner Lesslauer, Hansruedi Lotscher, Dietrich Stuber
-
Patent number: 5486463Abstract: The present invention is directed to a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 having a threonine instead of a serine residue, a DNA sequence coding for such a mutein, a vector comprising such a DNA sequence, and a host cell transformed by such a vector.Type: GrantFiled: April 1, 1993Date of Patent: January 23, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Werner Lesslauer, Hansruedi Lotscher, Dietrich Stuber